The stocks featured in this article have all approached their 52-week highs.
When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the drug development inputs & services industry, including UFP Technologies (NASDAQ:UFPT) and its peers.
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including IQVIA (NYSE:IQV) and its peers.
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Repligen (NASDAQ:RGEN) and its peers.
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations.
However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.
In a world where many businesses have shaky balance sheets, some have ignored the crowd and exercised prudence.
These cash-heavy companies shine bright for their financial discipline, resilience, and ability to generate solid returns.
Medpace’s third quarter results were well received by the market, driven by broad-based revenue growth and robust net new business awards. Management credited strong demand across therapeutic areas—particularly metabolic and obesity studies—and a significant increase in net bookings for lifting performance. CEO August Troendle pointed to a 30% year-over-year rise in awarded but not-yet-recognized work, which helped offset concerns about recent cancellations. CFO Kevin Brady added that improved productivity and lower employee-related costs also contributed to margin stability.
Medpace Holdings, Inc. (NASDAQ: MEDP), a leading global contract research organization (CRO), has been experiencing an unprecedented surge in its stock value, reaching an all-time high of $543.90 on October 1, 2025, and further climbing to $606.67 by October 24, 2025. This remarkable financial performance, which includes a 65.6% return over the past year and [...]
Clinical research company Medpace Holdings (NASDAQ:MEDP) reported revenue ahead of Wall Street’s expectations in Q3 CY2025, with sales up 23.7% year on year to $659.9 million. The company’s full-year revenue guidance of $2.51 billion at the midpoint came in 1.6% above analysts’ estimates. Its GAAP profit of $3.86 per share was 10% above analysts’ consensus estimates.
Clinical research company Medpace Holdings (NASDAQ:MEDP) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 23.7% year on year to $659.9 million. The company’s full-year revenue guidance of $2.51 billion at the midpoint came in 1.6% above analysts’ estimates. Its GAAP profit of $3.86 per share was 10% above analysts’ consensus estimates.
Medpace (MEDP) Q3 2025 earnings beat analyst forecasts with strong revenue and EPS growth. The CRO also reported robust bookings and raised its full-year guidance.
